Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 17,842 matching trials from the live ClinicalTrials.gov search.
Conditions
Pulmonary Embolism, Venous Thrombosis
Interventions
Enteric Coated Aspirin, Warfarin, Rivaroxaban
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
21 Years and older
Enrollment
18,883 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
30
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more
Conditions
Advanced MDS, Acute Myeloid Leukemia
Interventions
ARRY-520, KSP(Eg5) inhibitor; intravenous
Drug
Lead sponsor
Pfizer
Industry
Eligibility
17 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Atlanta, Georgia • Houston, Texas
Completed Phase 1 Interventional Accepts healthy volunteers

A TQTc Study for Omaveloxolone

NCT05927649
Conditions
Health Adult Subjects
Interventions
Omaveloxolone, Moxifloxacin
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Spinocerebellar Ataxia Type 3
Interventions
BIIB132, BIIB132-Matching Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Gainesville, Florida + 7 more
Conditions
Acute Respiratory Failure, Anxiety
Interventions
Dexmedetomidine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Zika Virus, Zika Virus Infection
Interventions
VLA1601, Placebo
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years to 49 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Renal Dialysis, Kidney Failure, Chronic
Interventions
MK-2060, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Orlando, Florida • Saint Paul, Minnesota • Knoxville, Tennessee
Conditions
Pancreatic Adenocarcinoma, Cancer of the Pancreas, Pancreas Cancer, Pancreatic Cancer
Interventions
Stereotactic body radiotherapy, Defactinib, Avutometinib
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Stroke, Acute
Interventions
Transcranial Direct Current Stimulation, Sham Stimulation
Device · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Multiple Myeloma
Interventions
RAD001, lenalidomide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Boston, Massachusetts • Rochester, Minnesota • New York, New York + 1 more
Conditions
Postacute Sequelae of Sars-CoV-2, Post-Acute COVID-19 Syndrome, Widespread Chronic Pain, Fatigue Syndrome, Chronic, Gait, Unsteady
Interventions
TENS - high-dose, TENS - low-dose
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Osteoarthritis, Osteoarthritis, Hip, Osteoarthritis, Knee, Pain, Arthralgia, Joint Pain
Interventions
JNJ-42160443, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
40 Years to 80 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more
Completed Not applicable Interventional Accepts healthy volunteers

Safety of Graded-Dose of Histidine in Humans

NCT04142294
Conditions
Healthy
Interventions
Histidine
Dietary Supplement
Lead sponsor
Cornell University
Other
Eligibility
21 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ithaca, New York
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

NCT04471038
Conditions
Influenza Type A, Influenza Type B, Influenza
Interventions
SAB-176, Normal Saline
Biological · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Conditions
Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell
Interventions
Alemtuzumab (Campath), EPOCH
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
17 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Parkinson Disease, Idiopathic Parkinson Disease
Interventions
N acetyl cysteine, [F-18] Fluorodopa Positron Emission Tomography
Dietary Supplement · Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Functional Iron Deficiency, Trauma, Anemia
Interventions
Iron sucrose, Oxandrolone, IV iron placebo, Oxandrolone placebo
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Interventions
Polatuzumab Vedotin, Rituximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
7
States / cities
Stanford, California • Sarasota, Florida • Buffalo, New York + 3 more
Conditions
Muscle Loss, Obesity
Interventions
Enobosarm, Semaglutide
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
60 Years to 100 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
14
States / cities
Anniston, Alabama • Cullman, Alabama • San Diego, California + 11 more
Conditions
Lung Cancer
Interventions
Tarceva (OSI-774), Paclitaxel, Carboplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Houston, Texas
Conditions
Prostate Cancer Metastatic
Interventions
HB-302/HB-301 Alternating 2-Vector Therapy
Biological
Lead sponsor
Hookipa Biotech GmbH
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
10
States / cities
Duarte, California • San Marcos, California • Miami, Florida + 5 more
Conditions
Acute Pain
Interventions
TRV130
Drug
Lead sponsor
Trevena Inc.
Industry
Eligibility
18 Years and older
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Mobile, Alabama • Pasadena, California • Miami, Florida + 6 more
Conditions
Atherosclerosis, Cardiovascular Disease
Interventions
MEDI6012 40 mg, Placebo, MEDI6012 120 mg, MEDI6012 300 mg, Placebo IV Push, MEDI6012 IV Push
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
60 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Anniston, Alabama • Jacksonville, Florida • Port Orange, Florida + 1 more
Conditions
Crohn Disease
Interventions
Mesna, Cyclophosphamide, Filgrastim, Apheresis catheter placement, Leukapheresis, Fludarabine, Methylprednisolone, Diphenhydramine, Acetaminophen, anti-thymocyte globulin (rabbit), lymphocyte immune globulin, Peripheral Blood Stem Cell Infusion, Cytoxan
Drug · Procedure · Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
13 Years to 28 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California